Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730767 | 0.79 | DYRK1A (0.50) | DYRK1AKDM4EPOLBCTDSP1 | |
| SCHEMBL15366279 | 0.78 | KDM4E (0.47) | KDM4EPOLBCTDSP1NR4A2 | |
| SCHEMBL29355504 | 0.78 | KDM4E (0.47) | KDM4EPOLBCTDSP1NR4A2 | |
| SCHEMBL16720863 | 0.74 | NR4A2 (0.49) | KDM4EPOLBNR4A2 | |
| SCHEMBL974676 | 0.71 | L3MBTL1 (0.56) | KDM4E | |
| SCHEMBL695359 | 0.70 | SCN2B (0.42) | DYRK1AKDM4EPOLBCTDSP1NR4A2 | |
| SCHEMBL732879 | 0.70 | KDM4E (0.41) | DYRK1AKDM4EPOLBCTDSP1NR4A2 | |
| SCHEMBL694065 | 0.70 | ALDH1A1 (0.36) | DYRK1AKDM4EPOLBCTDSP1NR4A2 | |
| SCHEMBL15466611 | 0.69 | HTR7 (0.49) | KDM4EPOLBCTDSP1NR4A2 | |
| SCHEMBL733151 | 0.69 | DYRK1A (0.47) | DYRK1AKDM4EPOLBCTDSP1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | DYRK1A 3719/4885KDM4E 3445/4885POLB 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.